Recent studies have indicated a notable decrease in prescriptions for anti-anxiety medications, especially benzodiazepines, in states where marijuana has been legalized. This phenomenon raises important questions about the implications for pharmaceutical companies that have long dominated the market for anxiety treatments.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…